Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB
Retrieved on:
Thursday, May 11, 2023
MDMC, REMS, MDAI, Depression, Therapy, MDEA, Mitigation, Methylone, Anxiety, Therapeutic index, Pathology, Pharmacokinetics, PCT, MDE, DSM-IV codes, Literature, OF, Patent, Patient, Post-traumatic stress disorder, USE, MBDB, Empathy, Salt, SALTS, MDMA, Safety, Pharmaceutical industry, Vaccine, Terran, PTSD
The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.
Key Points:
- The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.
- Terran believes that therapeutic options for patients should be equally diverse, with unique psychedelics and empathogens tailored to specific patient needs.
- Terran completed what is believed to be the first comprehensive salt and polymorph screen performed to date on this compound.
- Terran completed additional improvements including the synthesis of deuterated forms of racemic methylone, R-methylone, and S-methylone with improved pharmacokinetics.